Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 16/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | ATF4 | P18848 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24997364 | 0.87 | PTGES (0.43) | NPY5RUSP30ANO1PTGESPTGS2 | |
| SCHEMBL30053549 | 0.87 | PTGES (0.43) | NPY5RUSP30ANO1PTGESPTGS2 | |
| SCHEMBL24997979 | 0.83 | CASP3 (0.46) | NPY5RUSP30ATF4 | |
| SCHEMBL30053203 | 0.83 | CASP3 (0.46) | NPY5RUSP30ATF4 | |
| SCHEMBL24997967 | 0.83 | SMN1; SMN2 (0.39) | ATF4 | |
| SCHEMBL30053354 | 0.83 | ATF4 (0.43) | ATF4 | |
| SCHEMBL24997261 | 0.83 | ATF4 (0.43) | ATF4 | |
| SCHEMBL24997274 | 0.82 | ATF4 (0.43) | NPY5RATF4 | |
| SCHEMBL24997309 | 0.81 | ATF4 (0.42) | PTGESATF4 | |
| SCHEMBL30054170 | 0.81 | ATF4 (0.42) | PTGESATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230042881-A1 | MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230042881-A1 | MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, ATF1, DDIT3 | NPY5R 1318/4885USP30 2633/4885ANO1 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.